Our own Dr. Koren recently attended the American College of Cardiology Conference in Washington D.C., where he was interviewed about the Encore Research Group's involvement in an exciting Phase III trial.
"... We saw an average LDL Cholesterol lowering, without statins, of 57 percent, compared to Ezetimibe (Zetia) which was an 18 percent reduction..."
"... HDL increased slightly using Evolocumab, statistically signficant compared to Ezetimibe or placebo, about 6 to 8 percent."
> View the full video here
Tuesday, April 15, 2014 3:18:00 PM